Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
  • Medical Education
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Dermatology
        • Psoriasis
        • Diabetes
        • Hypoglycemia
        • Inflammatory Bowel Disease
        • Crohn's Disease
        • Ulcerative Colitis
        • Migraine
        • Alzheimer's Disease
        • Cognitive Health
        • Obesity
        • Obstructive Sleep Apnea
        • Breast Cancer - Early
        • Breast Cancer - Metastatic
        • Hematological Malignancy
        • Non-Small Cell Lung Cancer
        • Oncology Precision Medicine
        • Thyroid Cancer
        • Axial Spondyloarthritis
        • Psoriatic Arthritis
        • Resources
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
        • Inflammatory Bowel Disease
        • Cluster Headache
        • Migraine
        • Alzheimer's Disease
        • Cognitive Health
        • Obesity
        • Obstructive Sleep Apnea
        • Breast Cancer - Metastatic
        • Gastrointestinal Cancer
        • Hematological Malignancy
        • Oncology
        • Osteoporosis
        • Rheumatoid Arthritis
        • Resources
  • Independent Medical Education
    • Cardiovascular
      • Alopecia Areata
      • Atopic Dermatitis
      • Psoriasis
      • Diabetes
      • Crohn's Disease
      • Ulcerative Colitis
      • Migraine
      • Alzheimer's Disease
      • Obesity
      • Obstructive Sleep Apnea
      • Breast Cancer
      • Gastrointestinal Cancer
      • Hematological Malignancy
      • Non-Small Cell Lung Cancer
      • Oncology
      • Oncology Precision Medicine
      • Prostate Cancer
      • Axial Spondyloarthritis
      • Psoriatic Arthritis
  • Chat Contact Us
Lilly

You are now leaving the Lilly Medical Education website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical Education.

The Communicating Needs and Features of IBD Experiences (CONFIDE) Study

Loading icon

Methods

Crohn’s Disease

Ulcerative Colitis

US and EU flags indicating surveyed patients and HCPs home countries; laptop indicating online survey

CONFIDE Study

The Communicating Needs and Features of IBD Experiences (CONFIDE) Study was an online, quantitative, cross sectional survey of healthcare providers (HCPs) and patients, aiming to provide further understanding of the burden, barriers, and care experience of those living with inflammatory bowel disease (IBD), as well as to elucidate gaps in communication between HCPs and patients. Study results shown include HCPs and patients from the United States (US) and Europe (EU) (UK, France, Spain, Germany, and Italy).1

This study was sponsored by Eli Lilly and Company and conducted from July to September 2021.1

CONFIDE was an online survey to help understand quality of life of patients with IBD and communication gaps between HCPs and patients.

Approximately 700 HCPs and 1500 patients were included for survey questionnaire.
chevron-filled-down

There were 2 online, quantitative, cross sectional surveys each for HCPs and patients with IBD. Participants were required to meet the defined eligibility criteria, provide informed consent, and complete the full survey. Surveys were completed by a total of 415 US and 1,103 European patients and 200 US and 503 European HCPs.1,2


Survey Development

6 gastroenterologists provided input on the HCP and patient surveys for CONFIDE

The survey was developed by a panel of gastroenterologists from around the globe with experience in IBD patient reported outcomes research. They provided input for both the HCP and patient surveys.1,2


Survey Development2

5 patients with IBD provided input on CONFIDE patient survey.

Patients with IBD (n=5) gave input on the patient survey.


Gastroenterologists and patients from the US and the EU
Gastroenterologists and patients from the US and the EU

Adelphi Real World conducted further review sessions with additional gastroenterologists (n=2) and patients (n=2) in both the US and the UK to further test the validity of the materials prior to the CONFIDE survey launch
Healthcare provider
Key Eligibility Criteria for HCPs1
  • A gastroenterologist, internal medicine physician with GI focus, IBD nurse specialist (UK only), nurse practitioner (US only), or physician assistant (US only)
  • Responsible for making prescribing decisions for at least 10 patients per month with IBD, of which at least 5 of whom must be patients with moderate-to-severe disease
  • Spending 50% or more of working time actively seeing patients

HCP Demographics1

Targets were set in the US and UK with the goal of including ~15% nurse practitioners/specialists and physician assistants and 85% gastroenterologists to reflect clinical dynamics


Pie charts representing the break down of participants Pie charts representing the break down of participants
chevron-filled-down View description
Patient
Key Eligibility Criteria for Patients1,2
  • Aged ≥ 18 years
  • IBD diagnosed by an HCP (as reported by the patient)
  • Had active disease of at least moderate severity as defined by meeting at least one of the following criteria:
    • Received anti-TNF, anti integrin, JAK inhibitor, anti-IL-12/23, or immunomodulator within the past years
    • Received steroid treatment for at least 1 month in the past years
    • Hospitalized for at least 4 consecutive weeks in the past 5 years
  • No previous colectomy
  • Not >20% of the total sample with concomitant irritable bowel syndrome diagnosis

Survey Administration 1

Online Survey
Online survey collected information on:
  • Demographic/background
  • Experience and impact of symptoms
  • Disease burden
  • HCP-Patient Communication
To identify symptoms experienced by patients in the past month and ever,patients were asked to select from a list of 30 symptoms:

  1. Which symptoms they currently experienced (from in the last month)
  2. Which symptoms they ever experienced (ever suffered from)

Patients then ranked these symptoms with the greatest impact. Some of the symptoms provided include diarrhea,blood in stool, bowel urgency, increased stool frequency, urge incontinence, fatigue/tiredness, persistent abdominal pain, and bowel urgency related accidents.

HCPs ranked the most common symptoms reported by patients, those with the greatest perceived impact, and potential reasons for HCPs not proactively discussing certain symptoms with patients with IBD.

GI=Gastrointestinal; IBD=Inflammatory Bowel Disease; IL=Interleukin.

References

  1. Travis S, Potts Bleakman A, Dubinsky MC, et al. The communicating needs and features of IBD experiences (confide) study: US and European Patient and health care professional perceptions of the experience and impact of symptoms of moderate to severe ulcerative colitis. Inflamm Bowel Dis. 2023; doi: 10.1093/ibd/izad142 (Ahead of print).
  2. Schreiber S, Gibble TH, Dubinsky MC, et al. Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Burden and Impact of Bowel Urgency is Similar in Patients with Moderate to Severe Crohn’s Disease and Ulcerative Colitis. Poster presented at American College of Gastroenterology; 20-25 October 2023; Vancouver, Canada. Poster P-0678.

VV-MED-134811

Please rate your satisfaction with the content on the following statements:

Very Dissatisfied

Dissatisfied

Neutral

Satisfied

Very Satisfied

Credibility of information
Credibility of information
Relevance of the information to my needs
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Confidence to implement the learnings in my clinical practice

Please rate your satisfaction with the content on the following statements:

Credibility of information
Credibility of information
Very Satisfied
Very Dissatisfied
Relevance of the information to my needs
Relevance of the information to my needs
Very Satisfied
Very Dissatisfied
Confidence to implement the learnings in my clinical practice
Confidence to implement the learnings in my clinical practice
Very Satisfied
Very Dissatisfied
  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (XXX) XXX-XXXX

This site is intended for US Healthcare Professionals only.

4.4.53 05/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
Cookie Settings
Facebook X LinkedIn
Lilly